<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="370506">
  <stage>Registered</stage>
  <submitdate>11/04/2016</submitdate>
  <approvaldate>14/04/2016</approvaldate>
  <actrnumber>ACTRN12616000491460</actrnumber>
  <trial_identification>
    <studytitle>Beta Blocker Intolerance: Genetic Testing to Explain Side Effects
</studytitle>
    <scientifictitle>Beta Receptor Polymorphism and Intolerance to Beta Blockade in Patients with Heart Failure or Ischaemic Heart Disease  </scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Heart Failure</healthcondition>
    <healthcondition>Ischaemic Heart Disease</healthcondition>
    <healthcondition>Beta Blocker Intolerance</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Coronary heart disease</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients with heart failure or ischaemic heart disease plus a history of intolerance to beta blockers (e.g. metoprolol) will have their blood samples taken. DNA analysis will be conducted to determine if beta receptor polymorphisms are associated with intolerance to this class of medicine. </interventions>
    <comparator>The control group will be a set of patients with heart failure or ischaemic heart disease, but are tolerant to beta blockers. </comparator>
    <control>Active</control>
    <interventioncode>Diagnosis / Prognosis</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence of beta-1 receptor polymorphisms. This will be assessed by analysing the DNA of blood samples. </outcome>
      <timepoint>After DNA analysis is complete for all participants</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence of beta-2 receptor polymorphisms. This will be assessed by analysing the DNA of blood samples. </outcome>
      <timepoint>After DNA analysis is complete for all participants</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Comparative doses of beta blockers via review of patient medical records</outcome>
      <timepoint>After recruitment is complete</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Systolic Heart Failure NYHA II-IV or Ischaemic Heart Disease
At least one documented dose of beta blocker
Documented intolerance to beta blocker (cases) - wheeze / bradycardia
Documented tolerance to beta blockers (controls)

</inclusivecriteria>
    <inclusiveminage>30</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Diastolic Heart Failure
Hypertrophic Cardiomyopathy
Renal / Hepatic Failure
</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods>The incidence of particular receptor mutations will be compared between the cases and controls. Programs such as Microsoft Excel or SPSS will be used to perform the statistical analysis. T-test will be utilised to detect a significant difference.

Sample Size
The target sample size is 200. We assume that the participation rate will be as low as 65%, therefore we will endeavour to identify 300 candidates (150 cases + 150 controls) to assure a test population of 200

Power
With the target sample size of 200, we will have 80% power to detect a difference in receptor incidence of 20% or more. 

Example of calculation parameters (http://clincalc.com/Stats/SampleSize.aspx)

Two independent study groups
The Primary Endpoint is dichotomous 
Type I error 0.05
Beta-1 incidence in controls assumed to be 15% (expected incidence in general population) 
Beta-1 incidence in cases assumed to be 35% in this example
Power to detect such a difference is 80%

</statisticalmethods>
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry>False</patientregistry>
    <followup />
    <followuptype />
    <purposeobs>Screening</purposeobs>
    <duration>Cross-sectional</duration>
    <selection>Case control</selection>
    <timing>Retrospective</timing>
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/06/2016</anticipatedstartdate>
    <actualstartdate>1/09/2016</actualstartdate>
    <anticipatedenddate>30/04/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>WA</recruitmentstate>
    <hospital>Sir Charles Gairdner Hospital - Nedlands</hospital>
  </recruitment>
  <sponsorship>
    <primarysponsortype>University</primarysponsortype>
    <primarysponsorname>University of Western Australia </primarysponsorname>
    <primarysponsoraddress>School of Medicine and Pharmacology, University of Western Australia, M503. 35 Stirling Hwy. Nedlands, W.A. 6009</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>University of Western Australia</fundingname>
      <fundingaddress>School of Medicine and Pharmacology, University of Western Australia, M503. 35 Stirling Hwy. Nedlands, W.A. 6009</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Hospital</sponsortype>
      <sponsorname>Sir Charles Gairdner Hospital </sponsorname>
      <sponsoraddress>Monash Ave, Nedlands. W.A. 6009</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>A beta blocker is a type of medication that is commonly given to cardiac patients. This
medication has been shown to reduce the risk of death in patients who have suffered a heart attack, or in those who experience heart failure. Beta blockers are associated with some side effects that may affect individual patients differently and may prevent their use in certain patients.

In this project, the researchers will study the genetic differences between patients who can take this medicine and those who are unable to tolerate the side effects. At the end of the study, we hope to have improved our understanding of how genetic differences may affect the use of this important medication.
</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Sir Charles Gairdner Human Research Ethics Committee</ethicname>
      <ethicaddress>Sir Charles Gairdner Hospital, Monash Ave, Nedlands. W.A. 6009</ethicaddress>
      <ethicapprovaldate>8/08/2016</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate>29/03/2016</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Dr</title>
      <name>Brendan McQuillan</name>
      <address>School of Medicine and Pharmacology, University of Western Australia, M503. 35 Stirling Hwy. Crawley, W.A. 6009. </address>
      <phone>+61 8 6151 0834</phone>
      <fax />
      <email>brendan.mcquillan@uwa.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Brendan McQuillan</name>
      <address>School of Medicine and Pharmacology, University of Western Australia, M503. 35 Stirling Hwy. Crawley, W.A. 6009. </address>
      <phone>+61 8 6151 0834</phone>
      <fax />
      <email>brendan.mcquillan@uwa.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Brendan McQuillan</name>
      <address>School of Medicine and Pharmacology, University of Western Australia, M503. 35 Stirling Hwy. Crawley, W.A. 6009. </address>
      <phone>+61 8 6151 0834</phone>
      <fax />
      <email>brendan.mcquillan@uwa.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Brendan McQuillan</name>
      <address>School of Medicine and Pharmacology, University of Western Australia, M503. 35 Stirling Hwy. Crawley, W.A. 6009. </address>
      <phone>+61 8 6151 0834</phone>
      <fax />
      <email>brendan.mcquillan@uwa.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
  </contacts>
</ANZCTR_Trial>